These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26264921)

  • 1. From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.
    Pérez DI; Martínez A; Gil C; Campillo NE
    Curr Med Chem; 2015; 22(33):3789-806. PubMed ID: 26264921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
    Moss DE; Perez RG
    Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.
    Michalska P; Buendia I; Del Barrio L; Leon R
    Curr Top Med Chem; 2017; 17(9):1027-1043. PubMed ID: 27697052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.
    Pathak C; Kabra UD
    Bioorg Chem; 2024 Mar; 144():107152. PubMed ID: 38290187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.
    Akıncıoğlu H; Gülçin İ
    Mini Rev Med Chem; 2020; 20(8):703-715. PubMed ID: 31902355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acetylcholinesterase inhibitors for treatment of Alzheimer's disease].
    Shinagawa S; Shigeta M
    Brain Nerve; 2014 May; 66(5):507-16. PubMed ID: 24807367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.
    Rosini M; Simoni E; Caporaso R; Minarini A
    Future Med Chem; 2016 Apr; 8(6):697-711. PubMed ID: 27079260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Fridkin M; Youdim MB
    Curr Drug Targets; 2012 Jul; 13(8):1089-106. PubMed ID: 22676912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old and new acetylcholinesterase inhibitors for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1181-7. PubMed ID: 27459153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
    Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook].
    Hausner L; Frölich L
    Dtsch Med Wochenschr; 2019 Feb; 144(3):156-160. PubMed ID: 30703832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B; Haen E
    Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
    Son M; Park C; Rampogu S; Zeb A; Lee KW
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.